Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday

Perspective Therapeutics (NYSE:CATX - Get Free Report) is projected to post its quarterly earnings results after the market closes on Wednesday, March 26th. Analysts expect Perspective Therapeutics to post earnings of ($0.26) per share for the quarter.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded up $0.03 during midday trading on Friday, hitting $2.52. The stock had a trading volume of 933,336 shares, compared to its average volume of 987,665. The company's 50-day moving average price is $3.03 and its 200-day moving average price is $6.86. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday. Wedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 17th. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Finally, Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $14.56.

Remove Ads

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.